MAFLD: What Is It?

Houston Methodist

D. Victor

New Therapies in Primary Biliary Cholangitis and Approaches in Autoi…

UCLA Health

S. Iriana

Best Practices In Managing NAFLD / NASH

MedNews Week

D. Bernstein

Liver Fat, Iron, Fibrosis, (and T1): Quantitative MRI in Chronic Liv…

UCSF School of Medicine

M. A. Ohliger

The Fatty Liver Disease Epidemic

UPMC

M. Klinge

Updates in Cholestatic Liver Disease: PBC and PSC

University of Colorado Department of Medicine

A. Kalra

Primary Biliary Cholangitis: State of the Art in 2024

MUSC Health

K. Kowdley

Current Treatment of Metabolic Dysfunction Associated with Steatotic…

Indiana University School of Medicine Division of Gastroenterology and Hepatology

N. Samala

Using Resmetirom (THR-β Agonist) in Your Practice for MASH

Scripps Health

J. Gutierrez

Caring for the Post Liver Transplant Patient in the Primary Care Set…

University of Colorado Department of Medicine

B. Henderson, M. O'Meara

Heart and Liver Interactions

Houston Methodist DeBakey Heart and Vascular Center

S. Adeel Ahsan

Cutting Edge Diagnostics and Treatment for NAFLD

Northwestern Medicine Gastroenterology

M. E. Rinella, L. Van Wagner

Medical Management of Metabolic Associated Steatotic Liver Disease

Michigan Medicine

R. Fontana

NASH Update 2023

Icahn School of Medicine at Mount Sinai

M. B. Bansal

The Evolving Landscape of Non-Alcoholic Fatty Liver Disease (NAFLD) …

Cardiometabolic Health Congress (CMHC)

K. Cusi

Fatty Liver Disease: When to Refer?

Yale School of Medicine

NAFLD: Updates in Management

UChicago Medicine

M. E. Rinella

Updates on Management of NASH

Pennsylvania Society of Gastroenterology

T. Singh

New Treatments for Steatotic Liver Disease (SLD): Are We There Yet?

University of Miami

S. A. Harrison

Non-Alcoholic Fatty Liver Disease: Where Are We in 2023?

Houston Methodist

N. Gunn